Literature DB >> 33811125

Therapeutic Targeting of the Tumor Microenvironment.

Leire Bejarano1, Marta J C Jordāo1, Johanna A Joyce2,3.   

Abstract

Strategies to therapeutically target the tumor microenvironment (TME) have emerged as a promising approach for cancer treatment in recent years due to the critical roles of the TME in regulating tumor progression and modulating response to standard-of-care therapies. Here, we summarize the current knowledge regarding the most advanced TME-directed therapies, which have either been clinically approved or are currently being evaluated in trials, including immunotherapies, antiangiogenic drugs, and treatments directed against cancer-associated fibroblasts and the extracellular matrix. We also discuss some of the challenges associated with TME therapies, and future perspectives in this evolving field. SIGNIFICANCE: This review provides a comprehensive analysis of the current therapies targeting the TME, combining a discussion of the underlying basic biology with clinical evaluation of different therapeutic approaches, and highlighting the challenges and future perspectives. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33811125     DOI: 10.1158/2159-8290.CD-20-1808

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  101 in total

Review 1.  The Single-Cell Level Perspective of the Tumor Microenvironment and Its Remodeling by CAR-T Cells.

Authors:  Sanxing Gao; Ryohichi Sugimura
Journal:  Cancer Treat Res       Date:  2022

Review 2.  Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment.

Authors:  Giulia Petroni; Aitziber Buqué; Lisa M Coussens; Lorenzo Galluzzi
Journal:  Nat Rev Drug Discov       Date:  2022-03-15       Impact factor: 84.694

Review 3.  Clinical relevance of tumour-associated macrophages.

Authors:  Mikael J Pittet; Olivier Michielin; Denis Migliorini
Journal:  Nat Rev Clin Oncol       Date:  2022-03-30       Impact factor: 66.675

Review 4.  Fibroblast heterogeneity in prostate carcinogenesis.

Authors:  Sathyavathi ChallaSivaKanaka; Renee E Vickman; Mamatha Kakarla; Simon W Hayward; Omar E Franco
Journal:  Cancer Lett       Date:  2021-10-29       Impact factor: 8.679

5.  PET of Fibroblast-Activation Protein for Breast Cancer Diagnosis and Staging.

Authors:  David A Mankoff; Mark A Sellmyer
Journal:  Radiology       Date:  2021-10-12       Impact factor: 11.105

6.  Microfluidics for Cancer Biomarker Discovery, Research, and Clinical Application.

Authors:  Justina Žvirblytė; Linas Mažutis
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

7.  Silencing VDAC1 to Treat Mesothelioma Cancer: Tumor Reprograming and Altering Tumor Hallmarks.

Authors:  Swaroop Kumar Pandey; Renen Machlof-Cohen; Manikandan Santhanam; Anna Shteinfer-Kuzmine; Varda Shoshan-Barmatz
Journal:  Biomolecules       Date:  2022-06-27

8.  Cancer‑associated fibroblast‑induced M2‑polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor‑1 pathway.

Authors:  Shuhai Chen; Yuji Morine; Kazunori Tokuda; Shinichiro Yamada; Yu Saito; Masaaki Nishi; Tetsuya Ikemoto; Mitsuo Shimada
Journal:  Int J Oncol       Date:  2021-07-01       Impact factor: 5.650

Review 9.  Stimuli-Responsive Polymeric Nanoplatforms for Cancer Therapy.

Authors:  Di Chang; Yuanyuan Ma; Xiaoxuan Xu; Jinbing Xie; Shenghong Ju
Journal:  Front Bioeng Biotechnol       Date:  2021-06-25

Review 10.  Circadian regulation of cancer cell and tumor microenvironment crosstalk.

Authors:  Wenjing Xuan; Fatima Khan; Charles David James; Amy B Heimberger; Maciej S Lesniak; Peiwen Chen
Journal:  Trends Cell Biol       Date:  2021-07-13       Impact factor: 20.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.